ContraVir Pharmaceuticals names Dr Timothy M. Block to board
M2 - Thu Apr 24, 4:53AM CDT
Biopharmaceutical company ContraVir Pharmaceuticals (OTC BB:CTRV) disclosed on Wednesday that Dr Timothy M. Block, PhD has been appointed to its board of directors.
ContraVir Strengthens Its Board of Directors with the Addition of Virology Expert, Scientist, and Entrepreneur, Timothy M. Block, Ph.D.
Business Wire - Wed Apr 23, 2:00PM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), an emerging biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that Timothy M. Block, Ph.D. has joined the company's Board of Directors. A renowned researcher and opinion leader in the field of virology, Dr. Block is a professor and founder of the Hepatitis B Foundation. His scientific work centers on the study and treatment of chronic viral infections including hepatitis B and C, and herpes simplex virus. Dr. Block has invented or co-invented several compounds designed to treat liver cancer and viral infection.
Baxter International to Split into Two Businesses; Spherix Sues Cisco over 11 Patent Infringements
ACCESSWIRE - Thu Mar 27, 11:37PM CDT
Baxter International Inc. (NYSE: BAX) - For an in-depth report on Baxter International Inc. follow: www.BullTrends.com/stockquote/BAX
ContraVir Appoints James Sapirstein as Chief Executive Officer and Board Member
Business Wire - Thu Mar 20, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development of antiviral technologies, today announced the appointment of James Sapirstein as Chief Executive Officer, and a member of the ContraVir Board of Directors. Mr. Sapirstein will lead the Company's strategic growth plan for the future, and, in particular, the clinical development of FV-100 to treat shingles (herpes zoster) patients.